Becton, Dickinson and Company (BD) has announced a collaboration with CerTest Biotec for the development of a molecular diagnostic test for the monkeypox virus.

As part of the partnership, the companies will develop the VIASURE Monkeypox CE/IVD molecular test using the BD MAX molecular diagnostic open system reagent suite.

The reagent suite will also be used to validate the diagnostic test on the BD MAX System, which is a fully integrated, automated platform for nucleic acid extraction and real-time PCR.

The BD MAX System provides results for up to 24 samples, within three hours, across multiple conditions.

Available for BD MAX System users, the new RT-PCR detection kit is expected to help understand the global spread of the disease, said BD.

The company noted that the Monkeypox PCR Detection Kit for the BD MAX System will be provided in a lyophilized format similar to other CerTest tests.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The diagnostic kit comes in a tube that fits into the test-specific position on the BD MAX ExK TNA extraction strip that is provided by BD.

BD Molecular Diagnostics vice-president Nikos Pavlidis said: “Enabling labs to rapidly respond to unexpected challenges is the kind of evolving health care situations for which the BD MAX open system reagent suite is designed.

“Through our collaboration with CerTest and their ability to rapidly transfer assays on the BD MAX System, we will enable BD MAX System users around the world to access a test for the confirmation of monkeypox.”

The company offers a range of tests on the BD MAX System that cover sexually transmitted infections, respiratory infections, gastrointestinal infections, women’s health diagnostics and healthcare-associated infections.

For the system, BD provides a suite of open system reagents that allow labs to completely automate and streamline their Lab Developed Tests and develop complementary assays on the system in partnership with customers.